Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
grade C 28.0 2.53% 0.69
RDUS closed down 1.09 percent on Friday, October 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical RDUS trend table...

Date Alert Name Type % Chg
MACD Bullish Centerline Cross Bullish 2.53%
Overbought Stochastic Strength 2.53%
Stochastic Reached Overbought Strength 1.41%
Overbought Stochastic Strength 1.41%
Up 3 Days in a Row Strength 1.41%
Up 4 Days in a Row Strength 1.41%
Up 5 Days in a Row Strength 1.41%
MACD Bullish Signal Line Cross Bullish 3.49%
Up 3 Days in a Row Strength 3.49%
Up 4 Days in a Row Strength 3.49%

Older signals for RDUS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Cancer Drugs Breast Cancer Endocrine System Hormones Osteoporosis Amines Treatment Of Breast Cancer Antiestrogens Eisai Selective Estrogen Receptor Modulators
Is RDUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.97
52 Week Low 12.81
Average Volume 552,790
200-Day Moving Average 21.8982
50-Day Moving Average 25.8424
20-Day Moving Average 25.715
10-Day Moving Average 25.2685
Average True Range 1.1922
ADX 23.53
+DI 27.3552
-DI 17.7666
Chandelier Exit (Long, 3 ATRs ) 25.7734
Chandelier Exit (Short, 3 ATRs ) 26.5966
Upper Bollinger Band 28.3573
Lower Bollinger Band 23.0727
Percent B (%b) 0.8
BandWidth 20.550651
MACD Line 0.0737
MACD Signal Line -0.1879
MACD Histogram 0.2616
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 43.4 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -5.26
Price-to-Sales 1353.51
Price-to-Book 6.40
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.62
Resistance 3 (R3) 28.62 28.18 28.40
Resistance 2 (R2) 28.18 27.85 28.18 28.32
Resistance 1 (R1) 27.75 27.65 27.97 27.75 28.25
Pivot Point 27.31 27.31 27.42 27.31 27.31
Support 1 (S1) 26.88 26.98 27.10 26.88 26.37
Support 2 (S2) 26.44 26.78 26.44 26.30
Support 3 (S3) 26.01 26.44 26.22
Support 4 (S4) 26.01